The low P/S ratio of Angi Inc. reflects investor sentiment anticipating the company's limited growth prospects and inferior revenue outlook compared to the industry. Thus, it seems likely that the share price may not rise significantly in the near future.
Doubts linger on Angi Inc.'s transformation, as it grapples with lack of profitability and negative market response to its annual losses. The real question is if its current financial state justifies a long-term rise in share price.
Angi Inc股票讨论区
📊⚡️📊
对收益/指导的回应:
• $百事可乐 (PEP.US)$+2.8%, $E2open Parent (ETWO.US)$ +0.7%
其他新闻:
• $灿谷 (CANG.US)$ +23.5%(批准每股普通股0.50美元的特别股息或每股ADS1美元的特别股息)
• $El Pollo Loco (LOCO.US)$ +12.7%(申报每股1.50美元的特别股息;还批准了新的2000万美元股票回购计划)
• $KnowBe4 (KNBE.US)$ +11.4%(据... 称,KnowBe4即将被Vista Equity Partners收购)
对收益/指导的回应:
• $New Relic (NEWR.US)$ +3.8%(指导), $美国航空 (AAL.US)$ +2%(指导)
其他新闻:
• $DICE Therapeutics (DICE.US)$ +66.5%(宣布其对促炎细胞因子 IL-17 的口服小分子拮抗剂 DC-806 的 1 期临床试验得出 “阳性” 顶线数据)
• $Albireo Pharma (ALBO.US)$ +17.2%(报告了来自 Bylvay 第 3 阶段试验的正面顶线数据(odevix...
暂无评论